Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$462.13 USD
+5.26 (1.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $461.89 -0.24 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRTX 462.13 +5.26(1.15%)
Will VRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Stay Ahead of the Game With Vertex (VRTX) Q2 Earnings: Wall Street's Insights on Key Metrics
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Other News for VRTX
Earnings week ahead: AMD, PLTR, PFE, DIS, O, ET, SHOP, GILD, MCD, CAT, VTRS, BP, UBER, CGC, and more
KBRA Assigns Preliminary Ratings to VRTX 2025-HQ | VRTX Stock News
Here's How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200
ClearBridge Growth Portfolios Q2 2025 Commentary